Sera Prognostics, Inc. (SERA)

USD 8.18

(-0.37%)

Market Cap (In USD)

268.34 Million

Revenue (In USD)

306 Thousand

Net Income (In USD)

-36.24 Million

Avg. Volume

172.03 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4.9-12.355
PE
-
EPS
-
Beta Value
1.044
ISIN
US81749D1072
CUSIP
81749D107
CIK
1534969
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Ms. Evguenia Lindgardt M.B.A.
Employee Count
-
Website
https://seraprognostics.com
Ipo Date
2021-07-15
Details
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.